Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 1;45(3):446-453.
doi: 10.1097/IAE.0000000000004322. Epub 2025 Feb 17.

REAL-WORLD LONG-TERM OUTCOMES OF INTRAVITREAL FARICIMAB IN PREVIOUSLY TREATED CHRONIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Naveen R Ambati  1   2 , Adam Leone  1   2 , Daniel Brill  1   2 , Robert A Sisk  1   2
Affiliations

REAL-WORLD LONG-TERM OUTCOMES OF INTRAVITREAL FARICIMAB IN PREVIOUSLY TREATED CHRONIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Naveen R Ambati et al. Retina. .

Abstract

Purpose: To study the real-world outcomes of intravitreal faricimab (IVF) in long-standing neovascular age-related macular degeneration (nAMD) over a 1-year study period.

Methods: Retrospective single-center cohort study of patients with previously treated nAMD receiving IVF with at least 12 months of follow-up. Main outcome measures include injection intervals, visual acuity (VA), and optical coherence tomography features.

Results: A total of 263 eyes from 217 patients received 6.4 ± 2.3 IVF injections over 1 year. Injection interval increased after switching to IVF (5.9 ± 1.8 vs. 7.6 ± 2.4 weeks) ( P < 0.01). There was no improvement in VA after switching to IVF at any time period ( P > 0.15). Average CST decreased after the first IVF injection and was sustained for 1 year (313.7 ± 96.0 vs. 288.2 ± 80.6 µ m) ( P < 0.01). There was a statistically significant resolution of subretinal fluid but not IRF at all time points (40.8%-50.4%; P < 0.01). Persistent fluid after the first IVF injection was resolved in 34.4% (n = 45) by 1 year. IVF was discontinued in 31 eyes (11.8%), four (1.6%) that experienced intraocular inflammation.

Conclusion: Long-standing nAMD eyes switched to IVF experienced a significant extension in injection interval, stable visual acuity, improvement in CST, and resolution of fluid on OCT in many patients over 1 year.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Comparison of injection interval before switching to IVF versus longest tolerated interval on IVF (blue - injection interval before switching to IVF, orange - longest tolerated injection interval with IVF).
See this image and copyright information in PMC

References

    1. Gragoudas ES, Adamis AP, Cunningham ET, Jr., et al. . Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816. - PubMed
    1. Avery RL, Pieramici DJ, Rabena MD, et al. . Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363–372.e5. - PubMed
    1. Rosenfeld PJ, Brown DM, Heier JS, et al. . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431. - PubMed
    1. Heier JS, Brown DM, Chong V, et al. . Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537–2548. - PubMed
    1. Brown DM, Michels M, Kaiser PK, et al. . Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57–65.e5. - PubMed

MeSH terms